These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 33621843)

  • 1. Persistent SARS-2 infections contribute to long COVID-19.
    Jacobs JJL
    Med Hypotheses; 2021 Apr; 149():110538. PubMed ID: 33621843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis.
    Noval Rivas M; Porritt RA; Cheng MH; Bahar I; Arditi M
    Front Immunol; 2022; 13():941009. PubMed ID: 35874696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.
    Peluso MJ; Deitchman AN; Torres L; Iyer NS; Munter SE; Nixon CC; Donatelli J; Thanh C; Takahashi S; Hakim J; Turcios K; Janson O; Hoh R; Tai V; Hernandez Y; Fehrman EA; Spinelli MA; Gandhi M; Trinh L; Wrin T; Petropoulos CJ; Aweeka FT; Rodriguez-Barraquer I; Kelly JD; Martin JN; Deeks SG; Greenhouse B; Rutishauser RL; Henrich TJ
    Cell Rep; 2021 Aug; 36(6):109518. PubMed ID: 34358460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID.
    Vojdani A; Vojdani E; Saidara E; Maes M
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
    Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
    Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19.
    Hsu CJ; Lin WC; Chou YC; Yang CM; Wu HL; Cheng YH; Liu PC; Chang JY; Chen HY; Sun JR
    Microbiol Spectr; 2022 Feb; 10(1):e0236221. PubMed ID: 35196799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunology and immunopathology of COVID-19.
    Merad M; Blish CA; Sallusto F; Iwasaki A
    Science; 2022 Mar; 375(6585):1122-1127. PubMed ID: 35271343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes.
    Moody R; Sonda S; Johnston FH; Smith KJ; Stephens N; McPherson M; Flanagan KL; Plebanski M
    Front Immunol; 2022; 13():945021. PubMed ID: 36032086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient.
    Nakajima Y; Ogai A; Furukawa K; Arai R; Anan R; Nakano Y; Kurihara Y; Shimizu H; Misaki T; Okabe N
    J Infect Chemother; 2021 Feb; 27(2):387-389. PubMed ID: 33328135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
    Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
    BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans.
    Yang S; Jerome KR; Greninger AL; Schiffer JT; Goyal A
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33804667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection.
    Fröberg J; Diavatopoulos DA
    Curr Opin Infect Dis; 2021 Jun; 34(3):181-186. PubMed ID: 33899752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.
    Jarrott B; Head R; Pringle KG; Lumbers ER; Martin JH
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00911. PubMed ID: 35029046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.
    Gusev E; Sarapultsev A; Solomatina L; Chereshnev V
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response.
    Turner JS; Day A; Alsoussi WB; Liu Z; O'Halloran JA; Presti RM; Patterson BK; Whelan SPJ; Ellebedy AH; Mudd PA
    Front Immunol; 2020; 11():618402. PubMed ID: 33488630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection.
    Kim KS; Iwanami S; Oda T; Fujita Y; Kuba K; Miyazaki T; Ejima K; Iwami S
    Life Sci Alliance; 2021 Oct; 4(10):. PubMed ID: 34344719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity.
    Fang H; Wegman AD; Ripich K; Friberg H; Currier JR; Thomas SJ; Endy TP; Waickman AT
    Viruses; 2021 May; 13(5):. PubMed ID: 34063463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.